Elevance Health, Inc. (NYSE:ELV) Shares Purchased by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its holdings in Elevance Health, Inc. (NYSE:ELV) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 570 shares of the company’s stock after acquiring an additional 170 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Elevance Health were worth $210,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ELV. Diversify Advisory Services LLC increased its stake in shares of Elevance Health by 6.2% in the third quarter. Diversify Advisory Services LLC now owns 701 shares of the company’s stock worth $365,000 after acquiring an additional 41 shares during the period. Iridian Asset Management LLC CT increased its stake in shares of Elevance Health by 10.7% in the third quarter. Iridian Asset Management LLC CT now owns 39,154 shares of the company’s stock worth $20,360,000 after acquiring an additional 3,786 shares during the period. Catalyst Financial Partners LLC increased its stake in shares of Elevance Health by 2.9% in the third quarter. Catalyst Financial Partners LLC now owns 918 shares of the company’s stock worth $477,000 after acquiring an additional 26 shares during the period. HM Payson & Co. grew its position in Elevance Health by 16.1% during the third quarter. HM Payson & Co. now owns 730 shares of the company’s stock valued at $380,000 after buying an additional 101 shares during the period. Finally, AustralianSuper Pty Ltd grew its position in Elevance Health by 7.7% during the third quarter. AustralianSuper Pty Ltd now owns 8,505 shares of the company’s stock valued at $4,423,000 after buying an additional 607 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Elevance Health stock opened at $393.42 on Friday. The company’s 50 day simple moving average is $387.15 and its 200-day simple moving average is $440.60. The company has a market capitalization of $89.45 billion, a price-to-earnings ratio of 15.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. As a group, equities research analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be issued a $1.71 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.74%. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s payout ratio is 26.71%.

Analyst Ratings Changes

Several analysts recently commented on ELV shares. Truist Financial dropped their price target on shares of Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $485.00 target price on shares of Elevance Health in a research report on Friday, January 24th. Barclays raised their price target on shares of Elevance Health from $501.00 to $512.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Mizuho decreased their price target on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Finally, Stephens downgraded shares of Elevance Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $520.00 to $440.00 in a research note on Wednesday, January 22nd. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and an average target price of $517.03.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.